Manage, curate, and post-process clinical data all in one place.
Upload imaging and biomarker data.
Transform your information into structured and task-ready data.
Process data with your own tools or our integrated solutions to train your own AI model.
Integrate with novel AI software solutions
An integrated and secure solution for managing, analysing, and sharing clinical data.
Ethical data access and security are our core principles. We allow collaborative analytics of clinical data at scale by maintaining ownership and full control.
Our privacy and compliance programs implement and exceed all legislative requirements and applicable standards. For more information about our commitment to protecting data or if you want to report a concern please contact us at email@example.com.
Our solution ensures each data point is curated to the highest quality. Tag or fully annotate your images on a DICOM-web annotator, or let our imaging experts do this for you.
Collaborate with world leading hospitals and academic institutions. Partner with global biopharma companies to maximise value from your own curated data.
Experts in our field, passionate about change
Defining the future of healthcare
We are Unique
Qureight is the world's only AI powered platform dedicated towards lung diseases, delivering a customised sandbox experience for users.
We are Focused
We believe that highly curated data is key to developing the world's best AI lung models
We are Ethical
Our simple solution drives ethical research and reduces costs allowing users to deliver the best patient care.
Join us on our #Qureight·Journey
Are you interested in finding our more about our platform and our plans for growth? If you would like to find out more about Qureight please get in touch.
Do you have skills as a full stack developer, data scientist or image analyst? If you would like to find out more about joining Qureight please get in touch.
Latest Qureight News
Study aims to investigate correlations between image and serum collagen biomarkers to advance the clinical measurement of progression in fibrotic lung diseases.
Loss of blood volume in small vessels and increased blood volume in medium and large vessels demonstrates a “redistribution” throughout the pulmonary vasculature which may impair gas exchange in patients.